Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - milnacipran hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - milnacipran hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; propylene glycol; hypromellose; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; propylene glycol; hypromellose; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; propylene glycol; hypromellose; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - encorafenib, quantity: 75 mg - capsule, hard - excipient ingredients: magnesium stearate; copovidone; iron oxide black; gelatin; iron oxide red; iron oxide yellow; poloxamer; titanium dioxide; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; succinic acid - melanoma,encorafenib, in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by a validated test.,colorectal cancer,encorafenib, in combination with cetuximab, is indicated for the treatment of adult patients who have metastatic colorectal cancer (mcrc) with a braf v600e mutation as detected by a validated test, and who have received prior systemic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - encorafenib, quantity: 50 mg - capsule, hard - excipient ingredients: magnesium stearate; copovidone; iron oxide black; gelatin; iron oxide red; iron oxide yellow; poloxamer; titanium dioxide; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; succinic acid - melanoma,encorafenib, in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by a validated test.,colorectal cancer,encorafenib, in combination with cetuximab, is indicated for the treatment of adult patients who have metastatic colorectal cancer (mcrc) with a braf v600e mutation as detected by a validated test, and who have received prior systemic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - binimetinib, quantity: 15 mg - tablet, film coated - excipient ingredients: iron oxide black; macrogol 3350; colloidal anhydrous silica; purified talc; iron oxide yellow; microcrystalline cellulose; polyvinyl alcohol; magnesium stearate; titanium dioxide; croscarmellose sodium; lactose monohydrate - binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by a validated test.